Dexcom earns CGM reimbursement in France for type 2 diabetes

Dexcom (Nasdaq:DXCM) announced today that its Dexcom ONE sensor received reimbursement for those with type 2 […]

Dexcom (Nasdaq:DXCM) announced today that its Dexcom ONE sensor received reimbursement for those with type 2 diabetes in France.

The previous-generation Dexcom ONE sensor originally launched in France last fall. At that time, it covered patients two years and older with type 1 and type 2 diabetes undergoing intensive insulin therapy.

Now, the company can offer its continuous glucose monitor (CGM) technology to people in France aged over two years on on-intensified insulin therapy (less than 3 injections a day) and whose glycaemic control is insufficient (HbA1c ≥ 8%). France becomes the first country in Europe offering full national reimbursement for Dexcom CGM technology for those treating type 2 diabetes with basal injections. The country follows others around the world in that sense, including the U.S. and New Zealand.

Dexcom ONE continuously monitors glucose levels in real-time, sending values wirelessly to a compatible smart device through the app or receiver, which then display trend arrows to show the speed and direction that glucose levels are heading. It also has a range of customizable alerts and access to the Clarity data management software to provide remote data sharing with HCPs. It uses the G6 hardware platform with a different software experience. The company also has a next-generation version of this platform, the ONE+, which began rolling out earlier this year.

According to a news release, Dexcom also recently secured reimbursement for its sensors in Germany for those with type 2 on basal oral therapy.

“The decision by the French government to offer national reimbursement for Dexcom CGM to those treating their type 2 diabetes with basal insulin injections is a significant step forward in both the treatment and understanding of type 2 diabetes on both an individual and societal level,” said Alex Moussa, SVP and GM of Dexcom EMEA & LATAM. “We will continue to advocate for widening access to our life-changing technology for those living with type 2 diabetes. The science and economics are clear: our technology can significantly improve the management of type 2 diabetes, positively impact the lives of those living with the condition, and lead to cost savings for healthcare services.”

Original Article: (https://www.drugdeliverybusiness.com/dexcom-reimbursement-france-type-2-diabetes/)